Drug Profile


Alternative Names: G-2Me-PE; Glycyl-2-methyl-L-prolyl-L-glutamic acid; Glycyl-L-2-methylprolyl-L-glutamic acid; NNZ-2566

Latest Information Update: 10 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neuren Pharmaceuticals
  • Developer Neuren Pharmaceuticals;; Walter Reed Army Institute of Research
  • Class Glutamates; Neuropeptides; Neuroprotectants; Oligopeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Cytokine inhibitors; Glial cell modulators; Neuropeptide receptor modulators; Synaptic transmission modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome; Rett syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Brain injuries; Fragile X syndrome; Rett syndrome
  • Preclinical Autistic disorder; Multiple sclerosis

Most Recent Events

  • 31 May 2017 Neuren has composition of matter patent protection for trofinetide in Europe
  • 31 May 2017 Neuren receives patent allowance for trofinetide in the US for Fragile X syndrome and in Europe for Autistic disorders including Rett syndrome and Fragile X syndrome
  • 22 Mar 2017 Adverse event data from a phase II trial in Rett syndrome released by Neuren Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top